Yao Kunhou, Ma Yali, Ma Wanli, Hu Junhong, Wang Chenyu, Chen Jiangtao, Zhang Junjie, Hua Long, Ren Xuequn
Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
J Cancer Res Ther. 2014 Aug;10 Suppl 1:70-4. doi: 10.4103/0973-1482.139768.
The aim of this systematic review and meta-analysis was to evaluate the clinical efficacy of Shenqifuzheng (SQFZ) injection combined with chemotherapy in the treatment of advanced gastric cancer.
We conducted an electronic search by using PubMed, EMBASE, ASCO, ESMO and Chinese National Knowledge Infratructure (CNKI), databases. The randomized controlled trials about Shenqifuzheng injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric cancer were reviewed and collected. Pooled odds ratio (OR) for the response rate and KPS improvement were calculated using the software MetaAnalyst 3.1.
Fifteen trials met our inclusion criteria and finally included in this meta-analysis. The objective response rate (ORR) in patients treated with Shenqifuzheng injection combined with chemotherapy was much higher than that of chemotherapy only (OR = 1.66, 95% CI: 1.20-2.29) with statistical significance (P < 0.05). The pooled data showed the combined treatment can significant increase the Karnofsky score (KPS) compared with the chemotherapy only (OR = 3.74, 95% CI: 2.66-5.27 (P < 0.05).
SQFZ injection combined with chemotherapy treatment regimen can improve the clinical efficacy and performance status in patients with advanced gastric cancer compared with chemotherapy alone.
本系统评价和荟萃分析旨在评估参芪扶正(SQFZ)注射液联合化疗治疗晚期胃癌的临床疗效。
通过使用PubMed、EMBASE、美国临床肿瘤学会(ASCO)、欧洲肿瘤内科学会(ESMO)和中国知网(CNKI)数据库进行电子检索。回顾并收集了关于参芪扶正注射液联合化疗与单纯化疗治疗晚期胃癌的随机对照试验。使用MetaAnalyst 3.1软件计算缓解率和KPS改善的合并比值比(OR)。
15项试验符合纳入标准,最终纳入本荟萃分析。参芪扶正注射液联合化疗治疗患者的客观缓解率(ORR)远高于单纯化疗(OR = 1.66,95%CI:1.20 - 2.29),具有统计学意义(P < 0.05)。汇总数据显示,与单纯化疗相比,联合治疗可显著提高卡诺夫斯基评分(KPS)(OR = 3.74,95%CI:2.66 - 5.27,P < 0.05)。
与单纯化疗相比,SQFZ注射液联合化疗方案可提高晚期胃癌患者的临床疗效和身体状况。